What it is
Tirzepatide is a dual agonist: it activates both the GLP-1 and the GIP receptors — two incretin pathways — in a single weekly injection. Adding GIP to the GLP-1 action is the key difference from semaglutide, and a step toward the triple-agonist idea behind retatrutide.
How it works
The GLP-1 arm does what it does in semaglutide — appetite suppression, slowed gastric emptying, better glucose handling. The added GIP-receptor activity is thought to contribute additional metabolic effects, and some preclinical work suggests GIP activation may even blunt some of the nausea that GLP-1 activation causes, though reviewers caution this remains speculative and not fully validated in humans.
The evidence
Tirzepatide reported the largest average weight loss of the mainstream class in trials — reviews cite roughly 18% placebo-corrected weight loss, versus about 12% for semaglutide. Its dual action is associated with strong improvements in both blood-sugar control and weight. As always, trial averages describe populations, not any single person.
Side effects
The side-effect profile broadly resembles the GLP-1 class — predominantly gastrointestinal (nausea, vomiting, constipation, diarrhea). Preclinical models suggest tirzepatide may induce fewer GI adverse events than equipotent doses of semaglutide, but a network meta-analysis found overall GI tolerability broadly comparable across the class. Serious concerns discussed for the class (pancreatitis, gallbladder issues) apply here too.
Everything in the GLP-1 side-effects article — including the stop-and-call warning signs — applies to tirzepatide.
Regulatory status
FDA-approved under brand names for diabetes and weight management. Prescription-only, studied as a pharmaceutical product under supervision.
FAQ
On average trial weight loss it reported larger numbers, but 'stronger' oversimplifies — individual response, tolerability, and side effects vary. It's a different molecule with an added receptor target, not simply a bigger dose.
GIP is a second incretin hormone. Activating its receptor alongside GLP-1 appears to add metabolic benefit; claims that it reduces nausea are still under investigation.
No — it's a dual (GLP-1 + GIP) agonist. The triple agonist that adds glucagon is retatrutide.
Sources
This profile summarizes the following. Follow the links to read the originals — and remember that summaries age, so check for newer information.
- Comparative safety and side effects of semaglutide and tirzepatide (ScienceDirect)
- Hypophagia and weight loss by tirzepatide with fewer GI events vs semaglutide in preclinical models (PMC)
- GI adverse events with GLP-1 RA: systematic review & network meta-analysis (Int. J. Obesity)
Inclusion here is not endorsement of any source's claims; several are cited so you can compare how different outlets characterize the same evidence.
Reviewed by Remy — part of the PepConnection crew.